<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DEMEROL - meperidine hydrochloride injection, solution </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1>Demerol<span class="Sup">™</span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="f28d1a25-1200-44c6-a9da-9f5d55b02cf0"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First">meperidine hydrochloride injection, USP</p>
<p><span class="Bold"><span class="Emphasis">CII</span></span></p>
<p>Rx only</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ed4aefbe-24d5-4f14-b591-294a6a0f7b9e"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Meperidine hydrochloride is ethyl 1-methyl-4-phenylisonipecotate hydrochloride, a white crystalline substance with a melting point of 186°C to 189°C. It is readily soluble in water and has a neutral reaction and a slightly bitter taste. The solution is not decomposed by a short period of boiling.</p>
<p>DEMEROL injectable is supplied in Carpuject™ with luer lock of 2.5% (25 mg/1 mL), 5% (50 mg/1 mL), 7.5% (75 mg/1 mL), and 10% (100 mg/1 mL). Uni-Amp™ unit dose pak-ampuls of 5% solution (25 mg/0.5 mL), (50 mg/1 mL), (75 mg/1.5 mL), (100 mg/2 mL), and 10% solution (100 mg/1 mL). Multiple-dose vials of 5% and 10% solutions contain metacresol 0.1% as preservative.</p>
<p>The pH of DEMEROL solutions is adjusted between 3.5 and 6 with sodium hydroxide or hydrochloric acid.</p>
<p>DEMEROL, brand of meperidine hydrochloride, 5 percent solution has a specific gravity of 1.0086 at 20°C and 10 percent solution, a specific gravity of 1.0165 at 20°C.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="d0fb3b4c-9ee6-4d6a-a433-2de8b7fcc849"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Meperidine hydrochloride is a narcotic analgesic with multiple actions qualitatively similar to those of morphine; the most prominent of these involve the central nervous system and organs composed of smooth muscle. The principal actions of therapeutic value are <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> and sedation.</p>
<p>There is some evidence which suggests that meperidine may produce less smooth <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasm</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of the <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> reflex than equianalgesic doses of morphine. Meperidine, in 60 mg to 80 mg parenteral doses, is approximately equivalent in <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> to 10 mg of morphine. The onset of action is slightly more rapid than with morphine, and the duration of action is slightly shorter. Meperidine is significantly less effective by the oral than by the parenteral route, but the exact ratio of oral to parenteral effectiveness is unknown.</p>
<p>In clinical studies reported in the literature, changes in several pharmacokinetic parameters with increasing age have been observed. The initial volume of distribution and steady-state volume of distribution may be higher in elderly patients than in younger patients. The free fraction of meperidine in plasma may be higher in patients over 45 years of age than in younger patients.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="d7ec5af0-392f-4ff7-83bf-7b1770b8d7df"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">For the relief of moderate to severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></p>
<p>For preoperative medication</p>
<p>For
support of anesthesia</p>
<p>For obstetrical <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span></p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="e36f5ec2-f199-422a-9487-ed2f13da4472"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to meperidine.</p>
<p>Meperidine is contraindicated in patients who are receiving monoamine oxidase (MAO) inhibitors or those who have recently received such agents. Therapeutic doses of meperidine have occasionally precipitated unpredictable, severe, and occasionally fatal reactions in patients who have received such agents within 14 days. The mechanism of these reactions is unclear, but may be related to a preexisting hyperphenylalaninemia. Some have been characterized by <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, severe <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and have resembled the syndrome of acute narcotic <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. In other reactions the predominant manifestations have been <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">hyperexcitability</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>, and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Although it is not known that other narcotics are free of the risk of such reactions, virtually all of the reported reactions have occurred with meperidine. If a narcotic is needed in such patients, a sensitivity test should be performed in which repeated, small, incremental doses of morphine are administered over the course of several hours while the patient’s condition and vital signs are under careful observation. (Intravenous hydrocortisone or prednisolone have been used to treat severe reactions, with the addition of intravenous chlorpromazine in those cases exhibiting <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>. The usefulness and safety of narcotic antagonists in the treatment of these reactions is unknown.)</p>
<p>Solutions of DEMEROL and barbiturates are chemically incompatible.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="e39ef50f-b984-49bd-817f-94e8a941bfce"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug Dependence</span>.</span></span> Meperidine can produce <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug dependence</span> of the morphine type and therefore has the potential for being abused. Psychic <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, and tolerance may develop upon repeated administration of meperidine, and it should be prescribed and administered with the same degree of caution appropriate to the use of morphine. Like other narcotics, meperidine is subject to the provisions of the Federal narcotic laws.</p>
<p><span class="Italics"><span class="Emphasis">Interaction with Other Central Nervous System Depressants.</span></span> MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS (SEE <span class="Bold Italics"><span class="Emphasis">DOSAGE AND ADMINISTRATION</span></span>), SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">HYPOTENSION</span>, AND PROFOUND SEDATION OR <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">COMA</span> MAY RESULT.</p>
<p><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">Head Injury</span> and <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased Intracranial Pressure</span>.</span></span> The respiratory depressant effects of meperidine and its capacity to elevate cerebrospinal fluid pressure may be markedly exaggerated in the presence of <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span>, other intracranial lesions, or a preexisting increase in intracranial pressure. Furthermore, narcotics produce adverse reactions which may obscure the clinical course of patients with head injuries. In such patients, meperidine must be used with extreme caution and only if its use is deemed essential.</p>
<p><span class="Italics"><span class="Emphasis">Intravenous Use.</span></span> If necessary, meperidine may be given intravenously, but the injection should be given very slowly, preferably in the form of a diluted solution. Rapid intravenous injection of narcotic analgesics, including meperidine, increases the incidence of adverse reactions; severe <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, peripheral <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>, and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> have occurred. Meperidine should not be administered intravenously unless a narcotic antagonist and the facilities for assisted or controlled respiration are immediately available. When meperidine is given parenterally, especially intravenously, the patient should be lying down.</p>
<p><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span> and Other Respiratory Conditions.</span></span> Meperidine should be used with extreme caution in patients having an acute <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic attack</span>, patients with <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> or <span class="product-label-link" type="condition" conceptid="4307356" conceptname="Cor pulmonale">cor pulmonale</span>, patients having a substantially decreased respiratory reserve, and patients with preexisting <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, or <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercapnia</span>. In such patients, even usual therapeutic doses of narcotics may decrease respiratory drive while simultaneously increasing airway resistance to the point of <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>.</p>
<p><span class="Italics"><span class="Emphasis">Hypotensive Effect.</span></span> The administration of meperidine may result in severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in the postoperative patient or any individual whose ability to maintain blood pressure has been compromised by a depleted blood volume or the administration of drugs such as the phenothiazines or certain anesthetics.</p>
<p><span class="Italics"><span class="Emphasis">Usage in Ambulatory Patients.</span></span> Meperidine may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. The patient should be cautioned accordingly.</p>
<p>Meperidine, like other narcotics, may produce <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> in ambulatory patients.</p>
<p><span class="Italics"><span class="Emphasis">Usage in Pregnancy and Lactation.</span></span> Meperidine should not be used in pregnant women prior to the labor period, unless in the judgment of the physician the potential benefits outweigh the possible hazards, because safe use in pregnancy prior to labor has not been established relative to possible adverse effects on fetal development.</p>
<p>When used as an obstetrical analgesic, meperidine crosses the placental barrier and can produce <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of respiration and psychophysiologic functions in the newborn. Resuscitation may be required (see <span class="Bold Italics"><span class="Emphasis">OVERDOSAGE</span></span>).</p>
<p>Meperidine appears in the milk of nursing mothers receiving the drug.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="da03510d-22b8-40f7-92b7-81b744216182"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">As with all intramuscular preparations, DEMEROL intramuscular injection should be injected well within the body of a large muscle.</p>
<p><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">Supraventricular Tachycardias</span>.</span></span> Meperidine should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="314665" conceptname="Atrial flutter">atrial flutter</span> and other <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardias</span> because of a possible vagolytic action which may produce a significant increase in the ventricular response rate.</p>
<p><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span>.</span></span> Meperidine may aggravate preexisting <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> in patients with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive disorders</span>. If dosage is escalated substantially above recommended levels because of tolerance development, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> may occur in individuals without a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive disorders</span>.</p>
<p><span class="Italics"><span class="Emphasis">Acute Abdominal Conditions.</span></span> The administration of meperidine or other narcotics may obscure the diagnosis or clinical course in patients with acute abdominal conditions.</p>
<p><span class="Italics"><span class="Emphasis">Special Risk Patients.</span></span> Meperidine should be given with caution and the initial dose should be reduced in certain patients such as the debilitated, and those with severe impairment of hepatic or renal function, <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, Addison’s disease, and <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span> or <span class="product-label-link" type="condition" conceptid="195590" conceptname="Urethral stricture">urethral stricture</span>.</p>
<div class="Section" data-sectionCode="34082-8">
<a name="f081687e-2456-43c3-873d-a2b8a1c65651"></a><a name="section-7.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics"><span class="Emphasis">Geriatric Use.</span></span> Clinical studies of DEMEROL did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in response between the elderly and younger patients. In general, dose selection for an elderly patient should be low, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. (See <span class="Bold Italics"><span class="Emphasis">DOSAGE AND ADMINISTRATION</span></span>.)</p>
<p>Sedating drugs may cause <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> and oversedation in the elderly; elderly patients generally should be started on low doses of DEMEROL and observed closely.</p>
<p>This drug is known to be excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</p>
<p>Clinical studies indicate that differences in various pharmacokinetic parameters may exist between elderly and younger patients. (See <span class="Bold Italics"><span class="Emphasis">CLINICAL PHARMACOLOGY</span></span>.)</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ed448518-6541-4cdb-a5b7-78b9378070e9"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The major hazards of meperidine, as with other narcotic analgesics, are <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and, to a lesser degree, circulatory <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>; <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> have occurred.</p>
<p>The most frequently observed adverse reactions include <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, sedation, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>. These effects seem to be more prominent in ambulatory patients and in those who are not experiencing severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. In such individuals, lower doses are advisable. Some adverse reactions in ambulatory patients may be alleviated if the patient lies down.</p>
<p>Other adverse reactions include:</p>
<p><span class="Italics"><span class="Emphasis">Nervous System.</span></span> <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">Euphoria</span>, <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">dysphoria</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, uncoordinated muscle movements, severe <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, transient <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> and <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>. Inadvertent injection about a nerve trunk may result in sensory-motor <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> which is usually, though not always, transitory.</p>
<p><span class="Italics"><span class="Emphasis">Gastrointestinal.</span></span> <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, biliary tract spasm.</p>
<p><span class="Italics"><span class="Emphasis">Cardiovascular.</span></span> <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span> of the face, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (see <span class="Bold Italics"><span class="Emphasis">WARNINGS</span></span>), <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span> following intravenous injection.</p>
<p><span class="Italics"><span class="Emphasis">Genitourinary.</span></span> <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary retention</span>.</p>
<p><span class="Italics"><span class="Emphasis">Allergic.</span></span> <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, other <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span>, wheal and flare over the vein with intravenous injection.</p>
<p><span class="Italics"><span class="Emphasis">Other.</span></span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> at injection site; local tissue irritation and <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span> following subcutaneous injection, particularly when repeated; antidiuretic effect.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="c4aa9321-8e63-4549-a78c-ffef44ed5a40"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"><span class="Italics"><span class="Emphasis">Symptoms.</span></span> Serious overdosage with meperidine is characterized by <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> (a decrease in <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span> and/or tidal volume, Cheyne-Stokes respiration, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>), extreme <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> progressing to <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span> or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, skeletal muscle <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">flaccidity</span>, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> and <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">clammy</span> skin, and sometimes <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. In severe overdosage, particularly by the intravenous route, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> may occur.</p>
<p><span class="Italics"><span class="Emphasis">Treatment.</span></span> Primary attention should be given to the reestablishment of adequate respiratory exchange through provision of a patent airway and institution of assisted or controlled ventilation. The narcotic antagonist, naloxone hydrochloride, is a specific antidote against <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> which may result from overdosage or unusual sensitivity to narcotics, including meperidine. Therefore, an appropriate dose of this antagonist should be administered, preferably by the intravenous route, simultaneously with efforts at respiratory resuscitation.</p>
<p>An antagonist should not be administered in the absence of clinically significant respiratory or cardiovascular <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</p>
<p>Oxygen, intravenous fluids, vasopressors, and other supportive measures should be employed as indicated.</p>
<p><span class="Bold"><span class="Emphasis">NOTE:</span></span> In an individual physically dependent on narcotics, the administration of the usual dose of a narcotic antagonist will precipitate an acute withdrawal syndrome. The severity of this syndrome will depend on the degree of physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and the dose of antagonist administered. The use of narcotic antagonists in such individuals should be avoided if possible. If a narcotic antagonist must be used to treat serious <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in the physically dependent patient, the antagonist should be administered with extreme care and only one-fifth to one-tenth the usual initial dose administered.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="c2c9d591-ca8c-4f52-8f0e-94218c59475c"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold"><span class="Emphasis">For Relief of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></span></span></p>
<p>Dosage should be adjusted according to the severity of the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and the response of the patient. While subcutaneous administration is suitable for occasional use, intramuscular administration is preferred when repeated doses are required. If intravenous administration is required, dosage should be decreased and the injection made very slowly, preferably utilizing a diluted solution. The dose of DEMEROL should be proportionately reduced (usually by 25 to 50 percent) when administered concomitantly with phenothiazines and many other tranquilizers since they potentiate the action of DEMEROL.</p>
<p><span class="Italics"><span class="Emphasis">Adults.</span></span> The usual dosage is 50 mg to 150 mg intramuscularly or subcutaneously every 3 or 4 hours as necessary. Elderly patients should usually be given meperidine at the lower end of the dose range and observed closely.</p>
<p><span class="Italics"><span class="Emphasis">Children.</span></span> The usual dosage is 0.5 mg/lb to 0.8 mg/lb intramuscularly or subcutaneously up to the adult dose, every 3 or 4 hours as necessary.</p>
<p><span class="Bold"><span class="Emphasis">For Preoperative Medication</span></span></p>
<p><span class="Italics"><span class="Emphasis">Adults.</span></span> The usual dosage is 50 mg to 100 mg intramuscularly or subcutaneously, 30 to 90 minutes before the beginning of anesthesia. Elderly patients should usually be given meperidine at the lower end of the dose range and observed closely.</p>
<p><span class="Italics"><span class="Emphasis">Children.</span></span> The usual dosage is 0.5 mg/lb to 1 mg/lb intramuscularly or subcutaneously up to the adult dose, 30 to 90 minutes before the beginning of anesthesia.</p>
<p><span class="Bold"><span class="Emphasis">For Support of Anesthesia</span></span></p>
<p>Repeated slow intravenous injections of fractional doses (e.g., 10 mg/mL) or continuous intravenous infusion of a more dilute solution (e.g., 1 mg/mL) should be used. The dose should be titrated to the needs of the patient and will depend on the premedication and type of anesthesia being employed, the characteristics of the particular patient, and the nature and duration of the operative procedure. Elderly patients should usually be given meperidine at the lower end of the dose range and observed closely.</p>
<p><span class="Bold"><span class="Emphasis">For Obstetrical <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">Analgesia</span></span></span></p>
<p>The usual dosage is 50 mg to 100 mg intramuscularly or subcutaneously when <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> becomes regular, and may be repeated at 1- to 3-hour intervals.</p>
<p>Parenteral drug products should be inspected visually for particulate and discoloration prior to administration whenever solution and container permit.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="a3d0897f-3f38-4d58-a397-a63a3d7a81c7"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><span class="Bold"><span class="Emphasis">For Parenteral Use</span></span></p>
<p>Solutions of DEMEROL for parenteral use are clear and colorless and are available as follows:</p>
<a name="i5ab5bbd4-91bd-40b9-87b5-e36a84258486"></a><table>
<thead><tr class="First Last">
<th><span class="Bold"><span class="Emphasis">NDC Number</span></span></th>
<th>
<span class="Bold"><span class="Emphasis">   Container   </span></span><br>
</th>
<th>
<span class="Bold"><span class="Emphasis">Concentration</span></span><br>
</th>
<th>
<span class="Bold"><span class="Emphasis">  Fill (mL)  </span></span><br>
</th>
<th>
<span class="Bold"><span class="Emphasis">Quantity </span></span><br>
</th>
</tr></thead>
<tbody>
<tr class="First">
<td>54868-5808-0</td>
<td><p class="First">Carpuject with luer lock</p></td>
<td><p class="First">5% (50 mg/mL)</p></td>
<td><p class="First">1 </p></td>
<td><p class="First">10 </p></td>
</tr>
<tr>
<td>54868-3230-1</td>
<td><p class="First">Uni-Amp unit dose pak</p></td>
<td><p class="First">5% (50 mg)</p></td>
<td><p class="First">1 </p></td>
<td><p class="First">25 </p></td>
</tr>
<tr>
<td>54868-4751-0</td>
<td><p class="First">Uni-Amp unit dose pak</p></td>
<td><p class="First">10% (100 mg)</p></td>
<td><p class="First">1 </p></td>
<td><p class="First">25 </p></td>
</tr>
<tr class="Last">
<td>54868-4751-1</td>
<td><p class="First">Uni-Amp unit dose pak</p></td>
<td><p class="First">10% (100 mg)</p></td>
<td><p class="First">1 </p></td>
<td><p class="First">1 </p></td>
</tr>
</tbody>
</table>
<p>Carpuject™ are packaged in a Slim-Pak™ tamper detection package. To prevent needle-stick injuries, needles should not be recapped, purposely bent, or broken by hand. Blunt cannulas should not be recapped, purposely bent or broken by hand.</p>
<p><span class="Bold"><span class="Emphasis">NOTE:</span></span> The pH of DEMEROL solutions is adjusted between 3.5 and 6 with sodium hydroxide or hydrochloric acid. Multiple-dose vials contain metacresol 0.1 percent as preservative. No preservatives are added to the ampuls or Carpuject™ sterile cartridge units.</p>
<p>Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]</p>
<p>Demerol is not a trademark of Hospira.</p>
<p>Revised: June, 2010</p>
<p> </p>
<p>Printed in USA                    EN-2526</p>
<p>Hospira, Inc., Lake Forest, IL 60045</p>
<br><p><br></p>
<p>Additional bar code label applied by:<br>Physicians Total Care, Inc.<br>Tulsa, Oklahoma      74146<br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="d1a9730e-ad93-4f56-b20b-3d6b53ed720b"></a><a name="section-12"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - PACKAGE LABEL</h1>
<div class="Figure"><img alt="label ndc 54868-4751" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=53ddfe26-5a7e-4f39-8904-829a03538f63&amp;name=4751.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="e6da6b05-ff92-40bf-ac92-0b70a111d1c5"></a><a name="section-13"></a><p></p>
<h1></h1>
<div class="Figure"><img alt="label ndc 54868-5808" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=53ddfe26-5a7e-4f39-8904-829a03538f63&amp;name=5808.jpg"></div>
<br><br><div class="Figure"><img alt="label ndc 54868-3230" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=53ddfe26-5a7e-4f39-8904-829a03538f63&amp;name=3230.jpg"></div>
<br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DEMEROL 		
					</strong><br><span class="contentTableReg">meperidine hydrochloride injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5808(NDC:0409-1178)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MEPERIDINE HYDROCHLORIDE</strong> (MEPERIDINE) </td>
<td class="formItem">MEPERIDINE HYDROCHLORIDE</td>
<td class="formItem">50 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5808-0</td>
<td class="formItem">10  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 CARTRIDGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021171</td>
<td class="formItem">08/21/2007</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DEMEROL 		
					</strong><br><span class="contentTableReg">meperidine hydrochloride injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-3230(NDC:0409-1253)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MEPERIDINE HYDROCHLORIDE</strong> (MEPERIDINE) </td>
<td class="formItem">MEPERIDINE HYDROCHLORIDE</td>
<td class="formItem">50 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-3230-0</td>
<td class="formItem">25  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 AMPULE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021171</td>
<td class="formItem">04/11/1994</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DEMEROL 		
					</strong><br><span class="contentTableReg">meperidine hydrochloride injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-4751(NDC:0409-1256)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MEPERIDINE HYDROCHLORIDE</strong> (MEPERIDINE) </td>
<td class="formItem">MEPERIDINE HYDROCHLORIDE</td>
<td class="formItem">100 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-4751-0</td>
<td class="formItem">25  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 AMPULE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-4751-1</td>
<td class="formItem">1  in 1 BOTTLE, DISPENSING</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 AMPULE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021171</td>
<td class="formItem">03/11/2003</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DEMEROL 		
					</strong><br><span class="contentTableReg">meperidine hydrochloride injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-0616(NDC:0409-1181)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MEPERIDINE HYDROCHLORIDE</strong> (MEPERIDINE) </td>
<td class="formItem">MEPERIDINE HYDROCHLORIDE</td>
<td class="formItem">50 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METACRESOL</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-0616-0</td>
<td class="formItem">1  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">30 mL in 1 VIAL, MULTI-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021171</td>
<td class="formItem">07/13/2000</td>
<td class="formItem">06/30/2011</td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DEMEROL 		
					</strong><br><span class="contentTableReg">meperidine hydrochloride injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-3610(NDC:0409-1201)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MEPERIDINE HYDROCHLORIDE</strong> (MEPERIDINE) </td>
<td class="formItem">MEPERIDINE HYDROCHLORIDE</td>
<td class="formItem">100 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METACRESOL</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-3610-0</td>
<td class="formItem">1  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">20 mL in 1 VIAL, MULTI-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021171</td>
<td class="formItem">07/05/1995</td>
<td class="formItem">06/30/2011</td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>2ed9b59c-40be-4140-aa8e-1584dcd09329</div>
<div>Set id: 53ddfe26-5a7e-4f39-8904-829a03538f63</div>
<div>Version: 3</div>
<div>Effective Time: 20111228</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
